

Global Candida Infections Drugs Market Growth 2026-2032

<https://marketpublishers.com/r/GCEF8E9F8C21EN.html>

Date: April 2026

Pages: 111

Price: US\$ 3,660.00 (Single User License)

ID: GCEF8E9F8C21EN

Abstracts

The global Candida Infections Drugs market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

Candida infection is a yeast infection where the skin acts as a host organism, and the infection multiplies and grows with the period. Candida albicans are the most common species of this infection. Candida normally lives on the skin and inside the body, such as the throat, gut, mouth, and vagina, without causing problems. It can cause infections if it grows out of control or enters deep into the body.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the 'Candida Infections Drugs Industry Forecast' looks at past sales and reviews total world Candida Infections Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Candida Infections Drugs sales for 2026 through 2032. With Candida Infections Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Candida Infections Drugs industry.

This Insight Report provides a comprehensive analysis of the global Candida Infections Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Candida Infections Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Candida Infections Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Candida Infections Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Candida Infections Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Candida Infections Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Azole

Nystatin

Other

Segmentation by Application:

Beriberi

Jock Itch

Vaginal Infection

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

F. Hoffmann-La Roche Ltd

Mylan NV

Teva Pharmaceutical Industries Ltd

Sanofi

Pfizer Inc

GSK plc

Novartis AG

AstraZeneca

Johnson & Johnson Private Limited

Sun Pharmaceutical Industries Ltd

Merck & Co., Inc

Bristol-Myers Squibb Company

Lilly

Amgen Inc

Key Questions Addressed in this Report

What is the 10-year outlook for the global Candida Infections Drugs market?

What factors are driving Candida Infections Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Candida Infections Drugs market opportunities vary by end market size?

How does Candida Infections Drugs break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Candida Infections Drugs Annual Sales 2021-2032

- 2.1.2 World Current & Future Analysis for Candida Infections Drugs by Geographic Region, 2021, 2025 & 2032

- 2.1.3 World Current & Future Analysis for Candida Infections Drugs by Country/Region, 2021, 2025 & 2032

2.2 Candida Infections Drugs Segment by Type

- 2.2.1 Azole

- 2.2.2 Nystatin

- 2.2.3 Other

- 2.2.4 Candida Infections Drugs Sales by Type

- 2.2.4.1 Global Candida Infections Drugs Sales Market Share by Type (2021-2026)

- 2.2.4.2 Global Candida Infections Drugs Revenue and Market Share by Type (2021-2026)

- 2.2.4.3 Global Candida Infections Drugs Sale Price by Type (2021-2026)

2.3 Candida Infections Drugs Segment by Application

- 2.3.1 Beriberi

- 2.3.2 Jock Itch

- 2.3.3 Vaginal Infection

- 2.3.4 Other

- 2.3.5 Candida Infections Drugs Sales by Application

- 2.3.5.1 Global Candida Infections Drugs Sale Market Share by Application (2021-2026)

- 2.3.5.2 Global Candida Infections Drugs Revenue and Market Share by Application

(2021-2026)

2.3.5.3 Global Candida Infections Drugs Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Candida Infections Drugs Breakdown Data by Company

3.1.1 Global Candida Infections Drugs Annual Sales by Company (2021-2026)

3.1.2 Global Candida Infections Drugs Sales Market Share by Company (2021-2026)

3.2 Global Candida Infections Drugs Annual Revenue by Company (2021-2026)

3.2.1 Global Candida Infections Drugs Revenue by Company (2021-2026)

3.2.2 Global Candida Infections Drugs Revenue Market Share by Company
(2021-2026)

3.3 Global Candida Infections Drugs Sale Price by Company

3.4 Key Manufacturers Candida Infections Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Candida Infections Drugs Product Location Distribution

3.4.2 Players Candida Infections Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR CANDIDA INFECTIONS DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Candida Infections Drugs Market Size by Geographic Region
(2021-2026)

4.1.1 Global Candida Infections Drugs Annual Sales by Geographic Region
(2021-2026)

4.1.2 Global Candida Infections Drugs Annual Revenue by Geographic Region
(2021-2026)

4.2 World Historic Candida Infections Drugs Market Size by Country/Region
(2021-2026)

4.2.1 Global Candida Infections Drugs Annual Sales by Country/Region (2021-2026)

4.2.2 Global Candida Infections Drugs Annual Revenue by Country/Region
(2021-2026)

4.3 Americas Candida Infections Drugs Sales Growth

4.4 APAC Candida Infections Drugs Sales Growth

4.5 Europe Candida Infections Drugs Sales Growth

4.6 Middle East & Africa Candida Infections Drugs Sales Growth

5 AMERICAS

5.1 Americas Candida Infections Drugs Sales by Country

5.1.1 Americas Candida Infections Drugs Sales by Country (2021-2026)

5.1.2 Americas Candida Infections Drugs Revenue by Country (2021-2026)

5.2 Americas Candida Infections Drugs Sales by Type (2021-2026)

5.3 Americas Candida Infections Drugs Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Candida Infections Drugs Sales by Region

6.1.1 APAC Candida Infections Drugs Sales by Region (2021-2026)

6.1.2 APAC Candida Infections Drugs Revenue by Region (2021-2026)

6.2 APAC Candida Infections Drugs Sales by Type (2021-2026)

6.3 APAC Candida Infections Drugs Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Candida Infections Drugs by Country

7.1.1 Europe Candida Infections Drugs Sales by Country (2021-2026)

7.1.2 Europe Candida Infections Drugs Revenue by Country (2021-2026)

7.2 Europe Candida Infections Drugs Sales by Type (2021-2026)

7.3 Europe Candida Infections Drugs Sales by Application (2021-2026)

7.4 Germany

7.5 France

- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Candida Infections Drugs by Country
 - 8.1.1 Middle East & Africa Candida Infections Drugs Sales by Country (2021-2026)
 - 8.1.2 Middle East & Africa Candida Infections Drugs Revenue by Country (2021-2026)
- 8.2 Middle East & Africa Candida Infections Drugs Sales by Type (2021-2026)
- 8.3 Middle East & Africa Candida Infections Drugs Sales by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Candida Infections Drugs
- 10.3 Manufacturing Process Analysis of Candida Infections Drugs
- 10.4 Industry Chain Structure of Candida Infections Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 Candida Infections Drugs Distributors
- 11.3 Candida Infections Drugs Customer

12 WORLD FORECAST REVIEW FOR CANDIDA INFECTIONS DRUGS BY

GEOGRAPHIC REGION

- 12.1 Global Candida Infections Drugs Market Size Forecast by Region
 - 12.1.1 Global Candida Infections Drugs Forecast by Region (2027-2032)
 - 12.1.2 Global Candida Infections Drugs Annual Revenue Forecast by Region (2027-2032)
- 12.2 Americas Forecast by Country (2027-2032)
- 12.3 APAC Forecast by Region (2027-2032)
- 12.4 Europe Forecast by Country (2027-2032)
- 12.5 Middle East & Africa Forecast by Country (2027-2032)
- 12.6 Global Candida Infections Drugs Forecast by Type (2027-2032)
- 12.7 Global Candida Infections Drugs Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

- 13.1 F. Hoffmann-La Roche Ltd
 - 13.1.1 F. Hoffmann-La Roche Ltd Company Information
 - 13.1.2 F. Hoffmann-La Roche Ltd Candida Infections Drugs Product Portfolios and Specifications
 - 13.1.3 F. Hoffmann-La Roche Ltd Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.1.4 F. Hoffmann-La Roche Ltd Main Business Overview
 - 13.1.5 F. Hoffmann-La Roche Ltd Latest Developments
- 13.2 Mylan NV
 - 13.2.1 Mylan NV Company Information
 - 13.2.2 Mylan NV Candida Infections Drugs Product Portfolios and Specifications
 - 13.2.3 Mylan NV Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.2.4 Mylan NV Main Business Overview
 - 13.2.5 Mylan NV Latest Developments
- 13.3 Teva Pharmaceutical Industries Ltd
 - 13.3.1 Teva Pharmaceutical Industries Ltd Company Information
 - 13.3.2 Teva Pharmaceutical Industries Ltd Candida Infections Drugs Product Portfolios and Specifications
 - 13.3.3 Teva Pharmaceutical Industries Ltd Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.3.4 Teva Pharmaceutical Industries Ltd Main Business Overview
 - 13.3.5 Teva Pharmaceutical Industries Ltd Latest Developments
- 13.4 Sanofi

- 13.4.1 Sanofi Company Information
- 13.4.2 Sanofi Candida Infections Drugs Product Portfolios and Specifications
- 13.4.3 Sanofi Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.4.4 Sanofi Main Business Overview
- 13.4.5 Sanofi Latest Developments
- 13.5 Pfizer Inc
 - 13.5.1 Pfizer Inc Company Information
 - 13.5.2 Pfizer Inc Candida Infections Drugs Product Portfolios and Specifications
 - 13.5.3 Pfizer Inc Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.5.4 Pfizer Inc Main Business Overview
 - 13.5.5 Pfizer Inc Latest Developments
- 13.6 GSK plc
 - 13.6.1 GSK plc Company Information
 - 13.6.2 GSK plc Candida Infections Drugs Product Portfolios and Specifications
 - 13.6.3 GSK plc Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.6.4 GSK plc Main Business Overview
 - 13.6.5 GSK plc Latest Developments
- 13.7 Novartis AG
 - 13.7.1 Novartis AG Company Information
 - 13.7.2 Novartis AG Candida Infections Drugs Product Portfolios and Specifications
 - 13.7.3 Novartis AG Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.7.4 Novartis AG Main Business Overview
 - 13.7.5 Novartis AG Latest Developments
- 13.8 AstraZeneca
 - 13.8.1 AstraZeneca Company Information
 - 13.8.2 AstraZeneca Candida Infections Drugs Product Portfolios and Specifications
 - 13.8.3 AstraZeneca Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.8.4 AstraZeneca Main Business Overview
 - 13.8.5 AstraZeneca Latest Developments
- 13.9 Johnson & Johnson Private Limited
 - 13.9.1 Johnson & Johnson Private Limited Company Information
 - 13.9.2 Johnson & Johnson Private Limited Candida Infections Drugs Product Portfolios and Specifications
 - 13.9.3 Johnson & Johnson Private Limited Candida Infections Drugs Sales, Revenue,

Price and Gross Margin (2021-2026)

13.9.4 Johnson & Johnson Private Limited Main Business Overview

13.9.5 Johnson & Johnson Private Limited Latest Developments

13.10 Sun Pharmaceutical Industries Ltd

13.10.1 Sun Pharmaceutical Industries Ltd Company Information

13.10.2 Sun Pharmaceutical Industries Ltd Candida Infections Drugs Product

Portfolios and Specifications

13.10.3 Sun Pharmaceutical Industries Ltd Candida Infections Drugs Sales, Revenue,

Price and Gross Margin (2021-2026)

13.10.4 Sun Pharmaceutical Industries Ltd Main Business Overview

13.10.5 Sun Pharmaceutical Industries Ltd Latest Developments

13.11 Merck & Co., Inc

13.11.1 Merck & Co., Inc Company Information

13.11.2 Merck & Co., Inc Candida Infections Drugs Product Portfolios and

Specifications

13.11.3 Merck & Co., Inc Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 Merck & Co., Inc Main Business Overview

13.11.5 Merck & Co., Inc Latest Developments

13.12 Bristol-Myers Squibb Company

13.12.1 Bristol-Myers Squibb Company Company Information

13.12.2 Bristol-Myers Squibb Company Candida Infections Drugs Product Portfolios and Specifications

13.12.3 Bristol-Myers Squibb Company Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.12.4 Bristol-Myers Squibb Company Main Business Overview

13.12.5 Bristol-Myers Squibb Company Latest Developments

13.13 Lilly

13.13.1 Lilly Company Information

13.13.2 Lilly Candida Infections Drugs Product Portfolios and Specifications

13.13.3 Lilly Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.13.4 Lilly Main Business Overview

13.13.5 Lilly Latest Developments

13.14 Amgen Inc

13.14.1 Amgen Inc Company Information

13.14.2 Amgen Inc Candida Infections Drugs Product Portfolios and Specifications

13.14.3 Amgen Inc Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.14.4 Amgen Inc Main Business Overview

13.14.5 Amgen Inc Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Candida Infections Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Candida Infections Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Azole

Table 4. Major Players of Nystatin

Table 5. Major Players of Other

Table 6. Global Candida Infections Drugs Sales by Type (2021-2026) & (K Units)

Table 7. Global Candida Infections Drugs Sales Market Share by Type (2021-2026)

Table 8. Global Candida Infections Drugs Revenue by Type (2021-2026) & (\$ million)

Table 9. Global Candida Infections Drugs Revenue Market Share by Type (2021-2026)

Table 10. Global Candida Infections Drugs Sale Price by Type (2021-2026) & (US\$/Unit)

Table 11. Global Candida Infections Drugs Sale by Application (2021-2026) & (K Units)

Table 12. Global Candida Infections Drugs Sale Market Share by Application (2021-2026)

Table 13. Global Candida Infections Drugs Revenue by Application (2021-2026) & (\$ million)

Table 14. Global Candida Infections Drugs Revenue Market Share by Application (2021-2026)

Table 15. Global Candida Infections Drugs Sale Price by Application (2021-2026) & (US\$/Unit)

Table 16. Global Candida Infections Drugs Sales by Company (2021-2026) & (K Units)

Table 17. Global Candida Infections Drugs Sales Market Share by Company (2021-2026)

Table 18. Global Candida Infections Drugs Revenue by Company (2021-2026) & (\$ millions)

Table 19. Global Candida Infections Drugs Revenue Market Share by Company (2021-2026)

Table 20. Global Candida Infections Drugs Sale Price by Company (2021-2026) & (US\$/Unit)

Table 21. Key Manufacturers Candida Infections Drugs Producing Area Distribution and Sales Area

Table 22. Players Candida Infections Drugs Products Offered

Table 23. Candida Infections Drugs Concentration Ratio (CR3, CR5 and CR10) &

(2024-2026)

Table 24. New Products and Potential Entrants

Table 25. Market M&A Activity & Strategy

Table 26. Global Candida Infections Drugs Sales by Geographic Region (2021-2026) & (K Units)

Table 27. Global Candida Infections Drugs Sales Market Share Geographic Region (2021-2026)

Table 28. Global Candida Infections Drugs Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 29. Global Candida Infections Drugs Revenue Market Share by Geographic Region (2021-2026)

Table 30. Global Candida Infections Drugs Sales by Country/Region (2021-2026) & (K Units)

Table 31. Global Candida Infections Drugs Sales Market Share by Country/Region (2021-2026)

Table 32. Global Candida Infections Drugs Revenue by Country/Region (2021-2026) & (\$ millions)

Table 33. Global Candida Infections Drugs Revenue Market Share by Country/Region (2021-2026)

Table 34. Americas Candida Infections Drugs Sales by Country (2021-2026) & (K Units)

Table 35. Americas Candida Infections Drugs Sales Market Share by Country (2021-2026)

Table 36. Americas Candida Infections Drugs Revenue by Country (2021-2026) & (\$ millions)

Table 37. Americas Candida Infections Drugs Sales by Type (2021-2026) & (K Units)

Table 38. Americas Candida Infections Drugs Sales by Application (2021-2026) & (K Units)

Table 39. APAC Candida Infections Drugs Sales by Region (2021-2026) & (K Units)

Table 40. APAC Candida Infections Drugs Sales Market Share by Region (2021-2026)

Table 41. APAC Candida Infections Drugs Revenue by Region (2021-2026) & (\$ millions)

Table 42. APAC Candida Infections Drugs Sales by Type (2021-2026) & (K Units)

Table 43. APAC Candida Infections Drugs Sales by Application (2021-2026) & (K Units)

Table 44. Europe Candida Infections Drugs Sales by Country (2021-2026) & (K Units)

Table 45. Europe Candida Infections Drugs Revenue by Country (2021-2026) & (\$ millions)

Table 46. Europe Candida Infections Drugs Sales by Type (2021-2026) & (K Units)

Table 47. Europe Candida Infections Drugs Sales by Application (2021-2026) & (K Units)

- Table 48. Middle East & Africa Candida Infections Drugs Sales by Country (2021-2026) & (K Units)
- Table 49. Middle East & Africa Candida Infections Drugs Revenue Market Share by Country (2021-2026)
- Table 50. Middle East & Africa Candida Infections Drugs Sales by Type (2021-2026) & (K Units)
- Table 51. Middle East & Africa Candida Infections Drugs Sales by Application (2021-2026) & (K Units)
- Table 52. Key Market Drivers & Growth Opportunities of Candida Infections Drugs
- Table 53. Key Market Challenges & Risks of Candida Infections Drugs
- Table 54. Key Industry Trends of Candida Infections Drugs
- Table 55. Candida Infections Drugs Raw Material
- Table 56. Key Suppliers of Raw Materials
- Table 57. Candida Infections Drugs Distributors List
- Table 58. Candida Infections Drugs Customer List
- Table 59. Global Candida Infections Drugs Sales Forecast by Region (2027-2032) & (K Units)
- Table 60. Global Candida Infections Drugs Revenue Forecast by Region (2027-2032) & (\$ millions)
- Table 61. Americas Candida Infections Drugs Sales Forecast by Country (2027-2032) & (K Units)
- Table 62. Americas Candida Infections Drugs Annual Revenue Forecast by Country (2027-2032) & (\$ millions)
- Table 63. APAC Candida Infections Drugs Sales Forecast by Region (2027-2032) & (K Units)
- Table 64. APAC Candida Infections Drugs Annual Revenue Forecast by Region (2027-2032) & (\$ millions)
- Table 65. Europe Candida Infections Drugs Sales Forecast by Country (2027-2032) & (K Units)
- Table 66. Europe Candida Infections Drugs Revenue Forecast by Country (2027-2032) & (\$ millions)
- Table 67. Middle East & Africa Candida Infections Drugs Sales Forecast by Country (2027-2032) & (K Units)
- Table 68. Middle East & Africa Candida Infections Drugs Revenue Forecast by Country (2027-2032) & (\$ millions)
- Table 69. Global Candida Infections Drugs Sales Forecast by Type (2027-2032) & (K Units)
- Table 70. Global Candida Infections Drugs Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 71. Global Candida Infections Drugs Sales Forecast by Application (2027-2032) & (K Units)

Table 72. Global Candida Infections Drugs Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 73. F. Hoffmann-La Roche Ltd Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 74. F. Hoffmann-La Roche Ltd Candida Infections Drugs Product Portfolios and Specifications

Table 75. F. Hoffmann-La Roche Ltd Candida Infections Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 76. F. Hoffmann-La Roche Ltd Main Business

Table 77. F. Hoffmann-La Roche Ltd Latest Developments

Table 78. Mylan NV Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 79. Mylan NV Candida Infections Drugs Product Portfolios and Specifications

Table 80. Mylan NV Candida Infections Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 81. Mylan NV Main Business

Table 82. Mylan NV Latest Developments

Table 83. Teva Pharmaceutical Industries Ltd Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 84. Teva Pharmaceutical Industries Ltd Candida Infections Drugs Product Portfolios and Specifications

Table 85. Teva Pharmaceutical Industries Ltd Candida Infections Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 86. Teva Pharmaceutical Industries Ltd Main Business

Table 87. Teva Pharmaceutical Industries Ltd Latest Developments

Table 88. Sanofi Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 89. Sanofi Candida Infections Drugs Product Portfolios and Specifications

Table 90. Sanofi Candida Infections Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 91. Sanofi Main Business

Table 92. Sanofi Latest Developments

Table 93. Pfizer Inc Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 94. Pfizer Inc Candida Infections Drugs Product Portfolios and Specifications

Table 95. Pfizer Inc Candida Infections Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 96. Pfizer Inc Main Business

Table 97. Pfizer Inc Latest Developments

Table 98. GSK plc Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 99. GSK plc Candida Infections Drugs Product Portfolios and Specifications

Table 100. GSK plc Candida Infections Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 101. GSK plc Main Business

Table 102. GSK plc Latest Developments

Table 103. Novartis AG Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 104. Novartis AG Candida Infections Drugs Product Portfolios and Specifications

Table 105. Novartis AG Candida Infections Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 106. Novartis AG Main Business

Table 107. Novartis AG Latest Developments

Table 108. AstraZeneca Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 109. AstraZeneca Candida Infections Drugs Product Portfolios and Specifications

Table 110. AstraZeneca Candida Infections Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 111. AstraZeneca Main Business

Table 112. AstraZeneca Latest Developments

Table 113. Johnson & Johnson Private Limited Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 114. Johnson & Johnson Private Limited Candida Infections Drugs Product Portfolios and Specifications

Table 115. Johnson & Johnson Private Limited Candida Infections Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 116. Johnson & Johnson Private Limited Main Business

Table 117. Johnson & Johnson Private Limited Latest Developments

Table 118. Sun Pharmaceutical Industries Ltd Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 119. Sun Pharmaceutical Industries Ltd Candida Infections Drugs Product Portfolios and Specifications

Table 120. Sun Pharmaceutical Industries Ltd Candida Infections Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 121. Sun Pharmaceutical Industries Ltd Main Business

Table 122. Sun Pharmaceutical Industries Ltd Latest Developments

Table 123. Merck & Co., Inc Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 124. Merck & Co., Inc Candida Infections Drugs Product Portfolios and Specifications

Table 125. Merck & Co., Inc Candida Infections Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 126. Merck & Co., Inc Main Business

Table 127. Merck & Co., Inc Latest Developments

Table 128. Bristol-Myers Squibb Company Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 129. Bristol-Myers Squibb Company Candida Infections Drugs Product Portfolios and Specifications

Table 130. Bristol-Myers Squibb Company Candida Infections Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 131. Bristol-Myers Squibb Company Main Business

Table 132. Bristol-Myers Squibb Company Latest Developments

Table 133. Lilly Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 134. Lilly Candida Infections Drugs Product Portfolios and Specifications

Table 135. Lilly Candida Infections Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 136. Lilly Main Business

Table 137. Lilly Latest Developments

Table 138. Amgen Inc Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors

Table 139. Amgen Inc Candida Infections Drugs Product Portfolios and Specifications

Table 140. Amgen Inc Candida Infections Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 141. Amgen Inc Main Business

Table 142. Amgen Inc Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Candida Infections Drugs
- Figure 2. Candida Infections Drugs Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Candida Infections Drugs Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Candida Infections Drugs Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Candida Infections Drugs Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Candida Infections Drugs Sales Market Share by Country/Region (2025)
- Figure 10. Candida Infections Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Azole
- Figure 12. Product Picture of Nystatin
- Figure 13. Product Picture of Other
- Figure 14. Global Candida Infections Drugs Sales Market Share by Type in 2026
- Figure 15. Global Candida Infections Drugs Revenue Market Share by Type (2021-2026)
- Figure 16. Candida Infections Drugs Consumed in Beriberi
- Figure 17. Global Candida Infections Drugs Market: Beriberi (2021-2026) & (K Units)
- Figure 18. Candida Infections Drugs Consumed in Jock Itch
- Figure 19. Global Candida Infections Drugs Market: Jock Itch (2021-2026) & (K Units)
- Figure 20. Candida Infections Drugs Consumed in Vaginal Infection
- Figure 21. Global Candida Infections Drugs Market: Vaginal Infection (2021-2026) & (K Units)
- Figure 22. Candida Infections Drugs Consumed in Other
- Figure 23. Global Candida Infections Drugs Market: Other (2021-2026) & (K Units)
- Figure 24. Global Candida Infections Drugs Sale Market Share by Application (2025)
- Figure 25. Global Candida Infections Drugs Revenue Market Share by Application in 2026
- Figure 26. Candida Infections Drugs Sales by Company in 2026 (K Units)
- Figure 27. Global Candida Infections Drugs Sales Market Share by Company in 2026
- Figure 28. Candida Infections Drugs Revenue by Company in 2026 (\$ millions)
- Figure 29. Global Candida Infections Drugs Revenue Market Share by Company in 2026

Figure 30. Global Candida Infections Drugs Sales Market Share by Geographic Region (2021-2026)

Figure 31. Global Candida Infections Drugs Revenue Market Share by Geographic Region in 2026

Figure 32. Americas Candida Infections Drugs Sales 2021-2026 (K Units)

Figure 33. Americas Candida Infections Drugs Revenue 2021-2026 (\$ millions)

Figure 34. APAC Candida Infections Drugs Sales 2021-2026 (K Units)

Figure 35. APAC Candida Infections Drugs Revenue 2021-2026 (\$ millions)

Figure 36. Europe Candida Infections Drugs Sales 2021-2026 (K Units)

Figure 37. Europe Candida Infections Drugs Revenue 2021-2026 (\$ millions)

Figure 38. Middle East & Africa Candida Infections Drugs Sales 2021-2026 (K Units)

Figure 39. Middle East & Africa Candida Infections Drugs Revenue 2021-2026 (\$ millions)

Figure 40. Americas Candida Infections Drugs Sales Market Share by Country in 2026

Figure 41. Americas Candida Infections Drugs Revenue Market Share by Country (2021-2026)

Figure 42. Americas Candida Infections Drugs Sales Market Share by Type (2021-2026)

Figure 43. Americas Candida Infections Drugs Sales Market Share by Application (2021-2026)

Figure 44. United States Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 45. Canada Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 46. Mexico Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 47. Brazil Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 48. APAC Candida Infections Drugs Sales Market Share by Region in 2026

Figure 49. APAC Candida Infections Drugs Revenue Market Share by Region (2021-2026)

Figure 50. APAC Candida Infections Drugs Sales Market Share by Type (2021-2026)

Figure 51. APAC Candida Infections Drugs Sales Market Share by Application (2021-2026)

Figure 52. China Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 53. Japan Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 54. South Korea Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 55. Southeast Asia Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 56. India Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 57. Australia Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 58. China Taiwan Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 59. Europe Candida Infections Drugs Sales Market Share by Country in 2026

Figure 60. Europe Candida Infections Drugs Revenue Market Share by Country (2021-2026)

Figure 61. Europe Candida Infections Drugs Sales Market Share by Type (2021-2026)

Figure 62. Europe Candida Infections Drugs Sales Market Share by Application (2021-2026)

Figure 63. Germany Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 64. France Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 65. UK Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 66. Italy Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 67. Russia Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 68. Middle East & Africa Candida Infections Drugs Sales Market Share by Country (2021-2026)

Figure 69. Middle East & Africa Candida Infections Drugs Sales Market Share by Type (2021-2026)

Figure 70. Middle East & Africa Candida Infections Drugs Sales Market Share by Application (2021-2026)

Figure 71. Egypt Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 72. South Africa Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 73. Israel Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 74. Turkey Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 75. GCC Countries Candida Infections Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 76. Manufacturing Cost Structure Analysis of Candida Infections Drugs in 2026

Figure 77. Manufacturing Process Analysis of Candida Infections Drugs

Figure 78. Industry Chain Structure of Candida Infections Drugs

Figure 79. Channels of Distribution

Figure 80. Global Candida Infections Drugs Sales Market Forecast by Region (2027-2032)

Figure 81. Global Candida Infections Drugs Revenue Market Share Forecast by Region (2027-2032)

Figure 82. Global Candida Infections Drugs Sales Market Share Forecast by Type (2027-2032)

Figure 83. Global Candida Infections Drugs Revenue Market Share Forecast by Type (2027-2032)

Figure 84. Global Candida Infections Drugs Sales Market Share Forecast by Application

(2027-2032)

Figure 85. Global Candida Infections Drugs Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Candida Infections Drugs Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/GCEF8E9F8C21EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GCEF8E9F8C21EN.html>